A comprehensive analysis of ICPs revealed significantly higher levels of ICPs such as CD44, CD80, CD86, and CTLA-4 in the high-TKT expression group (Figure 7D), thereby allowing tumor cells to evade immune surveillance, and facilitating tumor progression (Supplementary Figure S1C). The gene discussed is CD86; the disease is neoplasm.